Eliminating Donor Variability in ADCC Assays –Implementation in QC Lot Release
Challenges of ADCC Assay Development Class I therapeutic antibodies achieve their clinical efficacy by binding to their target antigen and through Fragment... Read More
ACCELERATING BIOLOGICS DEVELOPMENT PROGRAMS WITH PHASE-APPROPRIATE READY-TO-USE POTENCY BIOASSAYS
Progressing Biotherapeutics to Clinic Faster Biological activity of a biotherapeutic is a Critical Quality Attribute (CQA), which needs to be accurately measured... Read More
Driving Robust ADCC and T Cell Redirection with KILR® CD16 Effector Cells
Class I therapeutic antibodies achieve their clinical efficacy not only by binding to their target antigen but also through Fc domain-mediated recruitment... Read More
The Key to Designing a Kinase Screening Project
The key to designing any scientific study is to carefully define the question you are asking – and designing a kinase inhibitor... Read More